Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia

Vaccine

Volumn 28, Issue 4, 2010, Pages 1117-1120

  Souza, Alessandra R ^a   Braga, Josefina A P ^a   de Paiva, Terezinha M ^b   Loggetto, Sandra R ^c   Azevedo, Raymundo S ^d   Weckx, Lily Y ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c Hematology Center   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Influenza vaccines; Sickle cell anemia; Virosome vaccines

Indexed keywords

INFLUENZA VACCINE; VIROSOME VACCINE;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; CHILD; DIARRHEA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; OTALGIA; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RHINITIS; SCHOOL CHILD; SEROCONVERSION; SICKLE CELL ANEMIA; SKIN EDEMA; SKIN INDURATION; SKIN PAIN; SKIN REDNESS; VIRUS STRAIN; VOMITING; WEAKNESS;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANTIBODIES, VIRAL; CHILD; DRUG TOXICITY; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; VACCINES, SUBUNIT; VACCINES, VIROSOME; YOUNG ADULT;

EID: 73949156951     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.046     Document Type: Article

References (35)

1. Zago M.A. Considerações gerais. Manual de diagnóstico e tratamento das doenças falciformes (2001), ANVISA, Brasília p. 7-12
2. Serjeant G.R., and Serjeant B.E. Sickle cell disease. 3rd ed. (2001), University Press, Oxford p. 153-166
3. Dover G.J., and Platt O.S. Sickle cell disease. In: Nathan D.G., and Orkin S.H. (Eds). Hematology of infancy and childhood. 5th ed. (1998), W.B. Saunders Company, Philadelphia p. 762-809
4. Glezen W.P. Influenza viruses. In: Feigin R.D., and Cherry J.D. (Eds). Textbook of pediatric infectious diseases. 4th ed. (1998), WB Saunders Co., Philadelphia 2024-2041
5. Paterson J.C.S., and Sprague C.C. Observation on the genesis of crises in sickle cell anemia. Am J Med 50 (1959) 1502
6. Greenberg H.B., and Piedra P.A. Immunization against viral respiratory disease: a review. Pediatr Infect Dis J. 23 (2004) S254-S261
7. Zanetti A.R., Amendola A., Besana S., Boschini A., and Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 20 (2002) B29-B32
8. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccine. Vaccine 21 (2003) 1769-1775
9. Herzog C., Metcalfe I.C., and Schaad U.B. Virosome influenza vaccine in children. Vaccine 20 (2002) B24-B28
10. Kanra G., Marchisio P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 23 (2004) 300-306
11. De Brujin I.A., Nauta J., Gerez L., and Palache A.M. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 103 1-2 (2004) 139-145
12. Glück R., Mischler R., Finkel B., Que J.U., Scarpa B., and Cryz Jr. S.J. Immunogenicity of new virosome vaccine in elderly people. Lancet 344 (1994) 160-163
13. Conne P., Gauthey L., Vernet P., Althaus B., Que J.U., Finkel B., et al. Immunogenicity of trivalent subunit versus virosome formulated influenza vaccines in geriatric patients. Vaccine 15 15 (1997) 1675-1679
14. Schaad U.B., Bühlmann U., Burger R., Ruedeberg A., Wilder-Smith A., Rutishauser M., et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 44 5 (2000) 1163-1167
15. Pregliasco F., Mensi C., Serpilli W., Speccher L., Masella P., and Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano) 13 1 (2001) 38-43
16. Ruf B.R., Colberg K., Frick M., and Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF 59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 32 4 (2004) 191-198
17. Zuccotti G.V., Zenga A., Durando P., Massone L., Bruzzone B., Sala D., et al. Immunogenicity and tolerability of a trivalent virosomal influenza vaccine in a cohort of HIV-infected children. J Intern Med Res 32 (2004) 492-499
18. Palmer D.F., Coleman M.T., Dowdle W.R., and Schild G.C. Hemagglutination-inhibition test. In: Welfare P.H.S. (Ed). Advanced laboratory techniques for influenza diagnosis (1975), U.S. Department of Health, Atlanta 25-62
19. The European Agency for the Evaluation of Medicinal Products (EMEA); Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccine (CPMP/BWP/214/96), London, March 12, 1997.
20. Glezen W.P., Glezen L.S., and Alcorn R. Trivalent, inactivated influenza virus vaccine in children with sickle cell disease. Am J Dis Child 137 (1983) 1095-1097
21. ® V a trivalent virosome subunit influenza vaccine: production. Vaccine 20 (2002) B17-B23
22. Glück R., and Metcalfe I.C. New technology platforms in the development of vaccines for the future. Vaccine 20 (2002) B10-B16
23. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 23S (2005) S1/26-S1/38
24. Weniger B.G., and Papania M.J. Alternative vaccine delivery methods. In: Plotkin A.S., Orenstein W.A., and Offit P.A. (Eds). Vaccine. 5th ed. (2008), W.B. Saunders, Philadelphia 1357-1392
25. Steinberg E., Overturf G.D., Portnoy B., Powars D.R., Boyer K.M., and Cherry J.D. Serologic and clinical response of children with sickle cell disease to bivalent influenza A split virus vaccine. J Pediatr 92 5 (1978) 823-825
26. Ballester O.F., Abdallah J.M., and Prasad A. Impaired IgM antibody responses to an influenza virus vaccine in adults with sickle cell anemia. Am J Hematol 20 (1985) 409-412
27. Ahonkhai V.I., Landesman S.H., Fikrig S.M., Schmalzer E.A., Brown A.K., and Cherubin C.E. Failure of pneumococcal vaccine in children with sickle cell disease. N Engl J Med 310 1 (1979) 26-27
28. Bjornson A.B., Falletta J.M., Verter J.I., Buchanan G.R., Miller S.T., Pegelow C.H., et al. Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. J Pediatr 129 6 (1996) 828-835
29. Frank A.L., Labotta R.J., Rao S., Frisone L.R., McVerry P.H., Samuelson J.S., et al. Haemophilus influenzae tipo b immunization of children with sickle cell diseases. Pediatrics 82 4 (1988) 571-575
30. Rubin L.G., Voulalas D., and Carmody L. Immunization of children with sickle cell disease with Haemophilus influenzae type b polysaccharide vaccine. Pediatrics 84 3 (1989) 509-513
31. Hord J., Windsor B., Koehler M., Blatt J., Janosky J., and Mirro J. Diminished antibody response to hepatitis B immunization in children with sickle cell disease. J Pediatr Hematol Oncol 24 7 (2002) 548-549
32. Groto H.Z.W., and Costa F.F. Pattern of splenic phagocytic function in Brazilian patients with sickle cell disease. Rev Paul Med 110 6 (1992) 262-266
33. Lane P.A. Sickle cell disease. Pediatr Clin North Am 43 3 (1996) 639-664
34. ®) in elderly subjects. Vaccine 24 (2006) 6629-6631
35. Center for Disease Control and Prevention and Control of Influenza: recomendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Weekly Rep 55 (2006) 1-42